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Summary
RSV lower respiratory tract infections (LRTI) are among the most common
diseases necessitating hospital admission in children. In addition to causing
acute respiratory failure, RSV infections are associated with sequelae such as
secondary bacterial infections and reactive airway disease. One characteristic
host response observed in severe RSV-induced LRTI and/or subsequent
development of asthma is increased expression of interleukin (IL)-10.
However, contradictory results have been reported regarding whether IL-10
inhibits asthmatic responses or intensifies the disease. We aimed to reconcile
these discordant observations by elucidating the role of IL-10 in regulating
the host response to RSV LRTI. In this study, we used a lung-specific, induc-
ible IL-10 over-expression (OE) transgenic mouse model to address this
question. Our results showed that the presence of IL-10 at the time of RSV
infection not only attenuated acute inflammatory process (i.e. 24 h post-
infection), but also late inflammatory changes [characterized by T helper
type 2 (Th2) cytokine and chemokine expression]. While this result appears
contradictory to some clinical observations where elevated IL-10 levels are
observed in asthmatic patients, we also found that delaying IL-10 OE until
the late immune response to RSV infection, additive effects rather than
inhibitory effects were observed. Importantly, in non-infected, IL-10 OE
mice, IL-10 OE alone induced up-regulation of Th2 cytokine (IL-13 and
IL-5) and Th2-related chemokine [monocyte chemoattractant protein 1
(MCP-1), chemokine (C-C motif) ligand 3 (CCL3) and regulated upon acti-
vation normal T cell expressed and secreted (RANTES)] expression.We iden-
tified a subset of CD11b+CD11c+CD49b+F4/80–Gr-1– myeloid cells as a
prinicipal source of IL-10-induced IL-13 production. Therefore, the aug-
mented pathological responses observed in our ‘delayed’ IL-10 over-
expression model could be attributed to IL-10 OE alone. Taken together, our
study indicated dual roles of IL-10 on RSV-induced lung inflammation
which appear to depend upon the timing of when elevated IL-10 is expressed
in the lung.
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Introduction
Viral infections of the respiratory tract result in a broad
spectrum of disease presentations, ranging from the
common cold to respiratory failure and occasionally death.
Clinical consequences of viral-triggered lower respiratory
tract infections (LRTI) such as bronchiolitis, apnoea and
asthma exacerbations are among the most prevalent causes
of acute hospitalizations in children. The epidemiological
role of respiratory syncytial virus (RSV) on mediating these
presentations in children is well defined [1–4]. Further,
several epidemiological studies have implicated childhood
RSV LRTI as an independent risk factor for the subsequent
development of chronic asthma [5,6], although we have an
incomplete understanding of the mechanistic role of RSV in
causing this late sequela.
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RSV is an enveloped, non-segmented, negative-sense,
single-stranded RNA virus whose genome encodes at least
11 different viral proteins. Unexpectedly, vaccine develop-
ment against recombinant surface proteins not only failed
to confer protection, but actually led to more severe pulmo-
nary disease upon RSV infection [7]. Similarly, an earlier
approach of challenging a vaccinated cohort with RSV
induced interleukin (IL)-10 and IL-4 production, accompa-
nied by exacerbation of lung histopathology [8]. These
results from the development of an RSV vaccine as well as
the extraordinary burden of disease necessitate an improved
understanding of the host response to RSV LRTI to identify
alternative therapeutic strategies.
IL-10 is a major anti-inflammatory cytokine. As stated, it
would be expected that in responses triggered by RSV, IL-10
expression is a necessary and beneficial host response
directed at regulating excessive proinflammatory cytokines
and chemokines from RSV-activated immune cells [9,10].
Clinically, however, controversial data have been reported
for the role of IL-10 in modulating RSV-induced inflamma-
tion. For instance, increased IL-10 and regulated upon acti-
vation normal T cell expressed and secreted (RANTES)
were found in nasopharyngeal secretions of children
infected with RSV [11], and this observation is consistent
with another 1-year follow-up study which showed that
high IL-10 was associated with post-bronchiolitis wheezing
[12,13]. Conversely, lower IL-10 levels were reported to be
associated with a higher frequency of bronchial asthma and
chronic obstructive pulmonary disease (COPD) [14,15].
Furthermore, helminth-infected asthmatic patients with
lower levels of IL-10 tended to have less T helper type 2
(Th2) cytokine production when compared to helminth-
free patients [16]. These discrepancies suggest that IL-10
may be a dual function cytokine that plays multiple roles in
modulating varied immune responses during RSV infec-
tions. In this study we utilized a lung-specific IL-10 over-
expression (OE) murine model to examine specifically the
effects of IL-10 on RSV-induced lung inflammation. As
IL-10 OE can be manipulated temporally by giving animals
a doxy-containing diet, we were able to investigate IL-10
effects at different stages of RSV infection (i.e. early phase
and late phase). Our results showed that indeed IL-10 plays
dual roles during RSV infection. While the presence of
IL-10 at the time of RSV infection inhibited both acute and
late inflammation, late OE of IL-10 caused further exacer-
bation of RSV-induced lung pathophysiology.
Materials and methods
Animals
All animal experiments were performed in accordance with
the National Institutes of Health guidelines and locally
approved by the University of Michigan’s Committee on
Use and Care of Animals (UCUCA). The tetracycline-
inducible, lung-specific human IL-10 OE transgenic FVB/n
mice were established previously in the laboratory [17].
Chow containing tetracycline (0·0625%) was purchased as
TestDiet from Purina (Richmond, IN, USA). With this
methodology, we achieve lung-specific, human IL-10 OE at
about half-maximal levels at day 3 and maximal expression
levels by day 5 following ad libitum access to TestDiet. Thus,
in this study mice were provided tetracycline chow ad
libitum 3 days prior to RSV intratracheal injection. To
determine the impact of IL-10 OE after the initiation of
RSV infection, tetracycline chow was provided 2 days after
RSV intratracheal injection in order to induce IL-10 OE
later in the disease course. Previous investigations have
characterized control mice [FVB/n wild-type, and single
transgenic mouse possessing only the tet-responsive,
human IL-10 construct (tet-O-CMV-huIL-10)], none of
which demonstrated tetracycline-inducible human IL-10
expression [17]. Therefore, in this study, 6–8 weeks single
transgenic FVB/n control mice (designated as ‘TG-’) and
bitransgenic mice (designated as ‘IL-10 OE’) were both pro-
vided ad libitum access to TestDiet.
RSV infection
Human RSV A strain isolated originally at the University of
Michigan Hospitals was grown in culture and isolated. The
ability of this isolate to induce acute lung injury has been
characterized previously, as reported extensively [18–21].
For RSV infection with this strain, mice were anaesthetized
with inhalational isoflurane and injected intratracheally
with ~1 ¥ 105 plaque-forming units (pfu) of virus. The
animals were examined at various time-points after chal-
lenge for chemokine and cytokine expression and histologi-
cal analysis. Normal rabbit serum and anti-mouse IL-10
immune serum utilized for the anti-IL-10 blocking experi-
ment were kindly provided by Dr Steven Kunkel at the
University of Michigan. The protocol for intraperitoneal
(i.p.) injection of the blocking serum has been described
previously [22].
Assessment of gene expression by real-time polymerase
chain reaction (PCR)
RNA was isolated from lung tissue following homogeniza-
tion in Trizol (Invitrogen Life Technologies, Carlsbad, CA,
USA), according to the manufacturer’s protocol. Then, 1 mg
of total RNA was reverse-transcribed in a 20-ml volume.
Messenger RNA expression was determined in 2 ml of
cDNA by TaqMan real-time PCR using a Realplex detection
system (Eppendorf, Inc., Hauppauge, NY, USA) with gene-
specific primers and probes labelled with 5′-FAM and
3′-TAMRA. Primers and probes used for the detection of
mRNA expression were purchased from Applied Biosystems
(Carlsbad, CA, USA). Primers and probes for RSV-n and
RSV-g were determined using primer/probe detection sets
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designed by PE Biosystems and purchased from Sigma-
Aldrich (St Louis, MO, USA) [23]. Reactions were incu-
bated for 2 min at 50°C, denatured for 10 min at 95°C
and subjected to 40 two-step amplification cycles with
annealing/extension at 60°C for 1 min followed by
denaturation at 95°C for 15 s. Murine glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) was used as an inter-
nal control for quantification of the total amount of cDNA
used in the reaction. Results are normalized to GAPDH
expression and presented as fold-increase in mRNA expres-
sion compared with the level detected in non-infected
control mice.
Bioplex assay
Whole lung protein samples were prepared by homogeniz-
ing tissue in phosphate-buffered saline (PBS) containing
0·1% Triton X-100 with protease inhibitor cocktail tablets
(Roche, Indianapolis, IN, USA). Lung homogenates were
spun at 15 000 g for 10 min. Supernatants were collected
and stored at -80°C until analysed for chemokine and
cytokine expression by multiplex assay (Bio-Rad, Hercules,
CA, USA).
Assessment of lung pathology
Mice lungs were dissected and inflation fixed in 10% buff-
ered formalin. The lungs were maintained in formalin for
24 h before being processed into paraffin blocks using
standard histological techniques. Lung tissue sections were
stained with both haematoxylin and eosin (H&E) for analy-
sis of peribronchial inflammatory cell accumulation and
periodic acid-Schiff (PAS) for assessment of mucus produc-
tion. To quantify mucus production in the lung, slides
stained with PAS were examined at ¥100 final magnification
using an Olympus IX71 microscope.
Pulmonary leucocyte isolation and
differential counting
Animals were euthanized by an approved protocol and
lungs were perfused with PBS via the right heart until
pulmonary vessels were grossly clear. Lungs were bluntly
dissected free from the chest cavity and minced to a slurry
in a suspension of digest solution containing collagenase
(15 mg), DNase I (250 KU units) and complete media
(RPMI-10% fetal calf serum). The suspension was incu-
bated on a rocker for 30 min at 37°C. The cells were dis-
persed by repetitive suction through a 10 cc syringe and
then spun down at 250 g for 10 min. After the supernatant
was decanted, each pellet was briefly resuspended with 1 ml
sterile ddH2O to lyse red blood cells and then recentrifuged.
Cell pellets were resuspended in 5 ml complete media and
passed through a 70 mm cell strainer. Cells were then
counted using a Beckman Coulter counter. Cytospins were
made by centrifuging 50 000 cells onto microscope slides
using a Shandon Cytospin. The slides were allowed to air-
dry and then stained with Diff-Quick Solution (Baxter Sci-
entific, Deerfield, IL, USA). Slides were rinsed in water and
allowed to air-dry. A total of 200 cells were counted from
four randomly chosen high-power microscope fields for
each sample. The differential percentage was multiplied by
the total leucocyte number to derive the absolute number of
monocyte/macrophages, polymorphonuclear cells (PMNs),
lymphocytes and eosinophils per sample.
CD4+ T cell depletion and flow cytometric sorting of
CD11b+ myeloid cells
On the same day, tetracycline-containing TestDiet was pro-
vided to the mice, and 1 mg of anti-CD4 antibody was
injected i.p. into mice. Twenty-four h and 11 days post-
antibody injection, red blood cell lysis was performed to
isolate and stain whole blood cells with fluorescein isothio-
cyanate (FITC)-labelled anti-CD3 and phycoerythrin (PE)-
labelled anti-CD4 antibodies. Stained cells were washed and
fixed with 1% paraformaldehyde overnight and kept in the
dark at 4°C until analysis using a fluorescence activated cell
sorter (FACS)Calibur flow cytometer (Becton Dickinson).
Half a million lung leucocytes in each test tube were used
for antibody staining and flow cytometric sorting. After
blocking non-specific binding with Fc blocker (BD Phar-
mingen, San Diego, USA), cells were stained with isotype
control or FITC-labelled anti-CD11b (from Pharmingen).
Stained cells were incubated at 4°C for 20 min and then
washed twice with FACS buffer [1 ¥ PBS, 0·2% bovine
serum albumin (BSA), 0·1% sodium azide] before sorting
on a BD Biosciences FACSVantage SE Cell Sorter.
Flow cytometry identification of IL-13-producing
myeloid cells in the IL-10 OE mice lung
Whole lung leucocytes were isolated from IL-10 OE mice
given doxy chow for 11 days. Cells were treated with
50 ug/ml phorbol myristate acetate (PMA) and 1 ug/ml
ionomycin in the presence of GolgiPlug and GolgiStop
(BD Pharmingen) for 5 h, spun down and resuspended in
FACS buffer (1 ¥ PBS, 0·2% BSA, 0·1% sodium azide). After
blocking non-specific binding with Fc blocker (BD
Pharmingen), the following antibodies were used for exam-
ining cell surface marker expression: FITC-conjugated
anti-CD11b (M1/70; BD Pharmingen); R-PE-conjugated
anti-CD11c (HL-3; BD Pharmingen); PE-conjugated anti-
CD49b (DX5; eBiosciences, San Diego, CA, USA); PE con-
jugated Gr-1 (RB6-8C5; Biolegend, San Diego, CA, USA);
and allophycocyanin (APC)-conjugated anti-F4/80 (BM8;
Biolegend). The following isotype control antibodies were
used for setting the myeloid cell gates: FITC-conjugated rat
IgG2b k (BD Pharmingen); R-PE-conjugated Ham IgG1 l1
(BD Pharmingen); PE-conjugated Rat immunoglobulin
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(Ig)M (eBiosciences); PE-conjugated rat IgG2b k (Bioleg-
end); and APC-conjugated rat IgG2a k (Biolegend). After
surface marker staining, lung leucocytes were fixed and per-
meabilized with BD Cytofix/Cytoperm kit and then incu-
bated with labelled anti-mouse IL-13 for 1 h at room
temperature (RT). The following anti-mouse IL-13 anti-
bodies and isotype controls were used: Alex 647-conjugated
anti-IL-13(eBio 13A; eBiosciences); PE-conjugated anti-IL-
13(eBio 13A; eBiosciences); Alex 647-conjugated rat IgG1 k
and PE-conjugated rat IgG1 k (eBiosciences). Positive stain-
ing of intracellular IL-13 was defined by comparing with
isotype controls and analysed using the Accuri C6 sampler
flow cytometer.
Statistical analysis
All statistics were performed using Graphpad Prism 4
(Graphpad, San Diego, CA, USA). Values were expressed as
the mean standard error of the mean. Significance was
assigned for P < 0·05. Data sets were analysed using Stu-
dent’s t-test or one-way analysis of variance (anova), with
individual group means being compared with the Student–
Newman–Keuls post-test.
Results
Effects of early IL-10 ‘turn on’ on
RSV-induced inflammation
Previous studies with this clinical isolate of RSV in suscepti-
ble mice identified two distinct phases of lung inflamma-
tion, i.e. acute phase (within 24 h, characterized in part by
increased cytokine and CXC chemokine expression medi-
ated via Toll-like receptor 3 activation) [24] and late phase
(days 8–10 post-infection, characterized by Th2 cytokine
production and increased mucus production and airway
hyperactivity) [18,25]. Based on these previous studies,
we examined the lungs of infected mice at both 24 h and 8
days post-RSV infections in the setting of lung-specific
IL-10 OE. At 24 h, the overall expression of chemokines
[keratinocyte-derived chemokine (KC), monocyte chem-
oattractant protein (MCP)-1, macrophage inflammatory
protein (MIP)-1a, inflammatory protein (IP)-10, MIP-2]
and cytokines [IL-1b, IL-6, IL-12 and interferon (IFN)-a]
was suppressed significantly in the IL-10 OE mice com-
pared to TG- mice (Fig. 1a,b). Cox-2, another important
mediator in RSV-induced lung pathology, was also inhibited
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Fig. 1. Over-expression of interleukin (IL)-10
in the lung inhibited respiratory syncitial virus
(RSV)-induced acute inflammation. Transgenic
(TG)- and IL-10 over-expression (OE) mice
were fed doxy chow 3 days prior to RSV
infection. At 24 h, mice lung were harvested and
snap-frozen for protein and RNA isolation.
Proteins extracted from lung tissue were
analysed by multiplex assay (Bio-Rad). Protein
values are reported as mean standard error of
the mean (s.e.m.) in pg/ml. RNA was isolated
using the Trizol method and analysed by
quantitative polymerase chain reaction (q-PCR)
using specific primer/probe. All mRNA values
are normalized to glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) expression and
reported as the mean s.e.m. fold-increase
compared with the level detected in
non-infected control mice. Mean values were
determined from n = 6 mice per experimental
group. *P < 0·05 and **P < 0·01 compared to
TG- RSV-infected mice.
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(Fig. 1a). Of note, at 24 h, Th2 cytokines were not induced
significantly either by RSV infection or by IL-10 OE
(Fig. 1c).
We next examined the effect of IL-10 OE at day 8 post-
RSV infection. We first measured endogenous mouse IL-10
and over-expressed human IL-10 levels by enzyme-linked
immunosorbent assay (ELISA) to demonstrate that human
IL-10, despite being over-expressed, did not induce signifi-
cant changes of endogenous IL-10 expression. We observed
that the over-expressed human IL-10 was about threefold
higher than endogenous IL-10 in both non-infected and
infected control mice (Fig. 2a). To determine the effects of
IL-10 OE on the late phase of inflammation (i.e. day 8), we
measured Th2-related chemokine (MCP-1), chemokine
(C-C motif) ligand 3 (CCL3) and RANTES] [26,27] and
Th1/Th2 cytokine (IFN-g, IL-12/IL-13, IL-5 and IL-4)
expression (Fig. 2b). Unexpectedly, we found that IL-10 OE
alone (without RSV infection) induced overall highly
up-regulated gene expression. For example, two of the most
highly unregulated genes were MCP-1 and IL-13, and their
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Fig. 2. Effects of early interleukin (IL)-10 ‘turn on’ on respiratory syncitial virus (RSV)-induced T helper type 1 (Th1)/Th2 inflammation and viral
clearance. Transgenic (TG)- and IL-10 over-expression (OE) mice were fed with doxy chow 3 days prior to RSV infection. At day 8, mice lung were
harvested for protein and RNA isolation. Proteins extracted from lung tissue were analysed by multiplex assay (Bio-Rad). Protein values are reported
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(q-PCR) using specific primer/probe. All mRNA values are normalized to glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) expression and
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protein levels (mouse and human). (b) Whole lung chemokine and cytokine expression. (c) Whole lung mucus gene expression. (d) Q-PCR analysis
of RSV surface protein G and nuclear protein N expression. Mean values were determined from n = 6–8 mice per experimental group; n.s.: not
significant. *P < 0·05 and **P < 0·01.
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expression levels were increased by ~4·5-fold and ~29-fold,
respectively, compared to the uninfected TG- group. CCL3,
RANTES, IFN-g, IL-5 and Cox-2 were also up-regulated,
albeit to a lesser degree (Fig. 2b). Conversely, IL-12 and IL-4
were not affected by IL-10 OE. As a result, in the early IL-10
‘turn on’ model, the IL-10 effects on RSV-induced late in-
flammation (day 8 post-RSV infection) were masked by the
IL-10 alone effects, because the majority of the increased
expression was attributed by IL-10 OE rather than RSV in-
fection. Among the genes examined, we were able to detect
changes of only IL-12, IL-4 and CCL3 gene expression. For
these three genes, IL-10 OE suppressed significantly their
expression induced by RSV infection (*P < 0·05).
In addition to chemokine and cytokine expression,
mucus gene expression (Muc5 and Gob5) was also highly
up-regulated by IL-10 OE alone after 8 days and this
increased expression was not up-regulated or down-
regulated further following RSV infection (Fig. 2c). Again,
IL-10 effects on RSV-induced mucus gene expression were
masked by the highly up-regulated Muc5 and Gob5 expres-
sion in the no RSV group. We also examined the effects of
early IL-10 ‘turn on’ on viral clearance by quantitative-PCR
(q-PCR) analysis on two RSV proteins, surface protein G
and nuclear protein N, at both days 6 and 8 post-infection
(Fig. 2d). Results showed that no significant differences
were detected between control mice and the IL-10 OE mice,
indicating that although early IL-10 ‘turn on’ altered the
lung inflammatory milieu, it did not affect clearance of the
virus.
Blocking endogenous IL-10 at the time of RSV
infection enhanced RSV-induced Th2 responses and
lung pathophysiology
Because of the IL-10 only effect, we aimed to distinguish
further the IL-10 effects on RSV-induced Th2 responses by
using an experimental approach of blocking endogenous
IL-10 at the time of RSV infection to evaluate Th2
responses (Fig. 3). Anti-IL-10 blocking was performed
as described previously [22]. Anti-IL-10 serum or non-
immune serum was injected i.p. into wild-type Fvb/n mice
immediately after RSV intrachacheal injection. Blocking
efficiency of endogenous IL-10 was examined at 24 h in
non-infected mice and at day 8 in RSV-infected mice. At
24 h, whole lung IL-10 levels decreased by approximately
half, and at day 8, IL-10 levels in the blocking group
remained significantly lower than in the control group
(Fig. 3a). In this setting, at day 8 both Th2 response genes
(IL-13, IL-5 and IL-4), Cox-2 (Fig. 3b) and mucus genes
(Muc5 and Gob5; Fig. 3c) were up-regulated significantly in
the blocking group. Furthermore, immunohistology analy-
sis showed that the degree of PAS-staining and the severity
of epithelial cell detachment in the anti-IL-10 blocking
group were significantly higher than in the control group
(Fig. 3d). Therefore, decreasing IL-10 levels at the time of
RSV infection strongly intensified Th2 responses and
pathological changes, which suggests strongly that early
IL-10 expression regulates RSV-induced lung inflammation
and pathophysiology negatively.
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OE of IL-10 increased leucocyte recruitment
independently into the lung
Because we found that IL-10 OE induced up-regulation of
Th2-related chemokine expression (MCP-1, RANTES and
CCL3, etc.) in the lung (Fig. 2b), we investigated the impact
of these elevated chemokines on leucocyte recruitment.
Immunohistology analysis consistently showed significantly
increased cellular infiltration in the lungs of the IL-10 OE
mice compared to mice not provided with doxy food
(Fig. 4). At day 9 of doxy diet, a mononuclear cell infiltra-
tion along the peribronchial and perivascular areas was
noted in the IL-10 OE mice, and modest mucus production
(examined by positive PAS staining) was detected along the
bronchial epithelials (middle panel). By day 11, cellular
infiltration became more intensified and PAS staining of the
lungs demonstrated both goblet cell hyperplasia and sub-
stantially increased mucus production (bottom panel). This
was not seen in bitransgenic mice not provided with doxy-
spiked chow (upper panel). To investigate further the nature
of the infiltrating cells, whole lung leucocytes were isolated
from mice provided with access to doxy food for a similar
time as in the above Fig. 1 experiment and subjected to dif-
ferential counting analysis (Table 1). Our data indicated
that IL-10 OE increased the total number of leucocytes in
the lung by ~two-fold compared to the control TG- mice,
with the majority of these cells being lymphocytes (~90%).
While only ~2–5% of the cells were monocytes, the total
number was increased by ~3–5-fold. Although the total
number of neutrophils in the IL-10 OE mice was not
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Fig. 3. Endogenous interleukin (IL)-10
blocking at the time of respiratory syncitial
virus (RSV) infection-intensified T helper type
2 (Th2) responses and lung pathophysiology.
Wild-type Fvb/n mice were infected with
~1 ¥ 105 plaque-forming units (pfu) of RSV
virus and injected intraperitoneally (i.p.) with
normal serum or anti-IL-10 serum immediately
after virus infection. At day 8, mice lung were
harvested for RNA isolation and lung section
preparation. (a) Enzyme-linked
immunosorbent assay (ELISA) measurement of
whole lung IL-10 levels at 24 h and 8 days after
anti-IL-10 blocking. (b) Quantitative
polymerase chain reaction (q-PCR) analysis of
cytokine gene expression at day 8
post-infection. (c) q-PCR analysis of mucus
gene expression at day 8 post-infection. (d)
Whole lung immunohistology analysis. Lung
tissue sections were stained with haematoxylin
and eosin (H&E) for analysis of inflammatory
cell accumulation and periodic acid-Schiff
(PAS) for assessment of mucus production.
Lung section preparation and staining were
performed as described in Materials and
methods. Final magnification ¥100. Sections
were representative of n = 5–6 mice per
experimental group.
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changed, the percentage of neutrophils was decreased by
~two-fold. Finally, whereas no eosinophils were detected in
TG- mice, about 1% of total cells in the IL-10 OE mice were
identified to be eosinophils.
CD4+ T cell depletion did not affect the IL-10-induced
IL-13 production
Among all the genes that we found up-regulated by IL-10
OE, IL-13 was the most highly expressed. IL-13 is known
to be produced by CD4+ Th2 cells during infection and is
a key component in the Th2 response [28]. During RSV
infection, RSV-specific IL-13-producing CD4+ effector T
cells had been suggested to be responsible for the develop-
ment of asthmatic responses [21,27]. To examine whether
IL-10 OE induced IL-13 production by CD4+ T cells or
other cell types, we depleted CD4+ T cells from the IL-10
OE mice using anti-CD4 antibody and then analysed IL-13
production by q-PCR. On the same day as introducing
TestDiet to the animals, 1 mg of anti-CD4 antibody was
injected i.p. into IL-10 OE mice. In the above Fig. 2 experi-
ment, mice were given TestDiet 3 days prior to RSV infec-
tion, and Th2 cytokine expression was analysed at day 8
post-infection. The total duration of TestDiet treatment is
11 days. Therefore, we chose day 11 and examined the
depletion efficiency by flow cytometry at both 24 h and
day 11 post-anti-IL-10 injection. Approximately 95% of
CD4+ T cells were depleted from the OE mice (Fig. 5a). Of
note, it has been shown to take ~3–4 weeks for the
depleted cells to repopulate [29]. At day 11, q-PCR analysis
of whole lung RNA showed that CD4+ T cell depletion did
not affect IL-13 and mucus gene expression (Fig. 5b).
Thus, these data indicated that IL-10-induced IL-13 pro-
duction was from cell populations other than CD4+ T cells.
It was reported recently that myeloid cells also produce
IL-13 [30–32]. Thus, to examine whether myeloid cells
in IL-10 OE induced IL-13 production in our model, we
harvested whole lung leucocytes and sorted CD11b+ cells
and analysed IL-13 expression by q-PCR. Significantly
increased IL-13 expression was detected from CD11b+ cells
sorted from IL-10 OE compared to the control TG- group
(Fig. 5c).
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Table 1. Differential leucocyte numbers in the lung following days of doxy chow treatment (¥ 106).
Day
Total cells PMN Lymphocyte Monocyte Eosinophil
TG- IL-10 OE TG- IL-10 OE TG- IL-10 OE TG- IL-10 OE TG- IL-10 OE
9 11·15 0·67 19·36 2·64 2·10 0·15 1·57 0·27 9·20 0·86 16·57 2·86 0·2 0·08 1·04 0·44 ND 0·31 0·07
14 10·64 0·57 26·00 4·00 3·72 0·42 4·87 1·13 6·25 0·25 19·23 2·07 0·48 0·08 1·23 0·57 ND 0·39 0·07
Number of differentials = percentage of differentials ¥ total lung leucocyte number. TG-: transgenic; IL: interleukin; OE: over-expression; PMN:
polymorphonuclear cells.
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Flow cytometry characterization of IL-13-producing
myeloid cells
To characterize further the source of IL-13-producing
myeloid cells, whole lung leucocytes isolated from IL-10 OE
mice (doxy day 11) were stained with different surface
markers for myeloid subtypes and analysed for intracellular
IL-13 expression by flow cytometry. As shown in Fig. 6,
fluorescence-labelled isotype controls were used for setting
the gates for dendritic cells (CD11b+/CD11c+; Fig. 6a),
natural killer (NK) cells (CD11b+/CD49b+; Fig. 6b), macro-
phages (CD11b+/F4/80+; Fig. 6c) and neutrophils (CD11b+/
Gr-1+; Fig. 6d) [33–35]. By comparing the fluorescence shift
of intracellular IL-13 staining and isotype control staining
(right panel), our analysis indicates that IL-13 was pro-
duced by dendritic cells and natural killer cells, but not
macrophages or neutrophils. Taken together, we conclude
that a subset of myeloid cells with the phenotype of
CD11b+CD11c+CD49b+Gr-1–F4/80– is the cellular source of
IL-13 production in the IL-10 OE mice.
Late IL-10 ‘turn on’ promoted RSV-induced
Th2 responses
Previous studies with RSV A strain have delineated distinct
stages of inflammation following virus infection, which are
characterized as early phase and late phase [36]. In charac-
terizing the expression of IL-10 in these phases we detected
high IL-10 expression at day 6, which then gradually
decayed at day 8 following RSV infection (Fig. 7a). Given
the clinical observation that elevated IL-10 levels in patients
during the late phases of RSV infection are associated with
airway bronchoconstriction [13], we surmise that over-
expressing IL-10 during the late phase of RSV-infection
would have a different immune regulatory effect from that
over-expressing IL-10 prior to the RSV infection. Therefore,
we gave the animals doxy chow 2 days after RSV infection
and examined Th2 cytokines, Th2-related chemokines and
mucus gene expression at day 8 post-RSV infection
(Fig. 7b,c). IL-10 OE-induced gene up-regulation was still
detected, albeit to a lesser degree (TG- noRSV versus IL-10
OE noRSV). With RSV infection, a further increased chem-
okine (MCP-1, RANTES) and cytokine (IL-13, IL-5) gene
expression were detected (IL-10 OE noRSV versus IL-10 OE
RSV; P < 0·05). Similar effects were observed on mucus
gene expression (Fig. 7c). Therefore, in contrast to the
inhibitory effects of IL-10 on RSV-induced inflammation
observed in the above experiment (Figs 1–3), an additive
effect was seen in this late IL-10 ‘turn on’ model (i.e. TG-
RSV versus IL-10 OE RSV). Histopathology of the lungs in
the IL-10 OE with RSV infection was also enhanced com-
pared to the infected TG- mice (Fig. 7d). q-PCR analysis on
RSV-g and RSV-n protein gene expression showed similar
expression levels between control mice and IL-10 OE mice,
indicating that late IL-10 ‘turn on’ enhanced Th2 responses
but did not affect viral clearance (Fig. 7e).
Discussion
To elucidate the varied roles of IL-10 in regulating
pathogen-induced immune responses, our laboratory estab-
lished a transgenic mouse model capable of inducible, lung-
× 100)
Doxy d9
No doxy
× 100)
× 100)
Doxy d11
Fig. 4. Lung immunohistology change induced by the over-expression
(OE) of interleukin (IL)-10. IL-10 OE mice were fed with TestDiet
(doxycycline-containing chow) for 9 and 11 consecutive days. Lung
section preparation and staining were performed as described in
Fig. 3. Final magnification ¥100. Sections are representative of n = 6
mice per group.
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specific IL-10 OE [17]. Given the frequent reports of
elevated IL-10 levels in children with severe lower respira-
tory tract viral infections and this cohort’s predisposition to
developing asthma, we aimed to elucidate the complex
regulatory role of IL-10 in viral-induced lung inflammation
using this transgenic mouse model. Our study demon-
strated that if IL-10 is present at the time of RSV infection,
it plays an overall anti-inflammatory role. IL-10 inhibits not
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Fig. 5. CD4+ T cell depletion and CD11b+ cell sorting. On the same day as introducing TestDiet to the animals, 1 mg of anti-CD4 antibody was
injected intraperitoneally (i.p.) into interleukin (IL)-10 over-expression (OE) mice. Mice that were not injected with depletion antibody were used as
controls. (a) Examination of CD4+ T cell depletion by flow analysis. The efficiency of CD4+ T cell depletion was analysed by flow at 24 h and day 11
after antibody injection. Whole blood isolation and staining are described in Materials and methods and CD4+ T cells were visualized as fluorescein
isothiocyanate (FITC)-CD3 and phycoerythrin (PE)-CD4 double-positive cells on the flowchart. (b) CD4+ T cell depletion did not affect IL-10
OE-induced IL-13 and mucus gene expression. Whole lung RNA was analysed at day 11 post-antibody injection. (c) Cell sorting of whole lung
CD11b+ cells. Transgenic (TG)- and IL-10 OE mice were given doxy chow diet for 11 days. At day 11, the right heart was perfused using
phosphate-buffered saline (PBS) and whole lung leucocytes were isolated using the collagenase method as described in Materials and methods.
CD11b+ myeloid cells were sorted by flow cytometer. Total RNA was extracted using the Trizol method and expression of IL-13 and mucus genes
were evaluated by quantitative polymerase chain reaction (q-PCR). Mean values were determined from n = 5 mice per experimental group.
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Fig. 6. Flow cytometry identification of interleukin (IL)-13-producing myeloid cells in the IL-10 over-expression (OE) mice lung. Whole lung
myeloid cell subsets were identified by specific cell surface markers: dendritic cells (CD11b+CD11c+); natural killer cells (CD11b+/CD49b+);
macrophages (CD11b+/F4/80+) and neutrophils (CD11b+/Gr-1+). Fluorescence-labelled isotype controls were used to set the gates of myeloid subsets
(left panel and middle panel). Intracellular expression of IL-13 was determined by comparing the fluorescence shift of anti-IL-13-stained cells and
isotype control stained cells (right panel) and analysed on the Accuri C6 sampler flow cytometer. IL-13-producing cells are characterized as
CD11b+CD11c+CD49b+ F4/80–Gr-1–. Flow data are representative of two to three independent experiments.
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Fig. 7. Late interleukin (IL)-10 ‘turn on’
promoted respiratory syncitial virus
(RSV)-induced inflammation without affecting
viral clearance. (a) Quantitative polymerase
chain reaction (q-PCR) analysis on endogenous
IL-10 expression during the course of RSV
infection. Mice lungs were harvested at days 1, 6
and 8 post-infection and analysed for
endogenous IL-10 expression by q-PCR. (b–d)
Both control and IL-10 over-expression (OE)
mice were infected with ~1 ¥ 105
plaque-forming units (pfu) of RSV virus. Two
days later, animals were switched to doxy chow
and mice lungs were harvested at day 8
post-RSV. Whole lung protein and total RNA
isolation were performed as described in Fig. 1.
Lung cytokine, chemokine and mucus gene
expression were analysed by q-PCR and
bio-plex for regulated upon activation normal T
cell expressed and secreted (RANTES) in (b)
and (c). In (d), lung pathology was examined by
staining with haematoxylin and eosin (H&E)
for analysis of inflammatory cell accumulation
and periodic acid-Schiff (PAS) for assessment of
mucus production. Final magnification ¥100.
(e) q-PCR analysis on RSV surface protein G
and nuclear protein N gene expression. Mean
values were determined from n = 6–8 mice per
experimental group.
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only acute inflammation but also RSV-triggered late Th1/
Th2 responses. Contradictory to the anti-inflammatory role
against virus infection, our data also showed that IL-10 OE
alone altered substantially the histological appearance of the
lung characterized by significantly increased mononuclear
cell infiltration, goblet cell hyperplasia and mucus pro-
duction. Further characterization of the infiltrating
cells indicated T cell predominance which correlated with
the up-regulation of Th2-related chemokines (MCP-1,
RANTES and CCL3), known to mediate lymphocyte and
eosinophil chemotaxis in the lung [37–40]. Importantly, we
observed highly up-regulated IL-13 expression and moder-
ately increased IL-5 in the IL-10 OE mice, indicating that
IL-10 OE is independently capable of inducing a Th2-
predominant environment in the lung in the absence of a
pathogen. These findings were somewhat surprising, given
the commonly described inhibitory effect on chemokine
expression attributed to IL-10 in acute lung injury [41].
Conversely, it also indicated the dual roles of IL-10 in
modulating inflammation.
It has been demonstrated in murine RSV models that
RSV-specific CD4+ and CD8+ effector T cells are key
contributors to the development of asthmatic responses
[27,42,43]. More recently, it has also been reported that
regulatory T cells suppress airway hyperresponsiveness and
tissue remodelling by secretion of IL-10 [44]. Under these
conditions, IL-10 appears to be a negative regulator against
viral-specific effector T cell responses [42,45]. The specifi-
city of IL-10 effects on antigen-specific T cell activities was
also demonstrated in other allergic models. For example,
Zuany-Amorim showed that ovalbumin (OVA)-induced
eosinophilic airway inflammation was decreased by
co-administration of recombinant mIL-10 and antigen
[46]. Moreover, Nakagome et al. found that IL-10 sup-
pressed Th2 cytokine production only from CD4+ T cells
that were restimulated by in vitro co-culture with OVA and
APC, whereas anti-CD3 or PMA-activated CD4+ T cell
functions were not inhibited by IL-10 [47]. Taken together,
we extrapolated that in the clinical studies, where a reverse
relationship between IL-10 and asthmatic responses were
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observed, IL-10’s anti-inflammatory effects might be due to
its negative regulation on viral-specific effector CD4+ T cells
[14,15]. Plus, RSV-induced Cox-2 gene expression was
inhibited by IL-10. Cox-2 is another important mediator
involved in RSV-induced inflammation, and Cox-2-
mediated prostaglandin E2 (PGE2) production was reported
to repress RSV-induced Th1 response, thereby promoting
Th2 responses [48].
In contrast to these anti-inflammatory effects on
pathogen-induced inflammation, IL-10 itself might target
cell types other than viral-specific effector T cells. In our
study, when CD4+ T cells were depleted by anti-CD4 anti-
body, IL-10 induced IL-13 up-regulation was not changed.
Cell sorting experiments demonstrated that lung CD11b+
myeloid cells were able of producing IL-13 by IL-10.
Further flow cytometry analysis on the myeloid subsets
showed positive intracellular IL-13 staining in CD11b+ den-
dritic cells and NK cells, but not in CD11b+ macrophages
and neutrophils; therefore, the IL-10 OE-induced IL-13-
producing cell was predicted to be a non-B/non-T (NBNT)
cell. In recent years, Th2-cytokine-producing NBNT cells
have been reported from several research laboratories
[31,32,49], and the phenotypes and functions of these
NBNT cells have varied depending on the types of infec-
tious agents and the developmental stages of the NBNT
cells. For example, Petersen et al. identified an IL-4- and
IL-13-producing Lin–c-Kit+Sca-1+IL-17RB+CD11b+Gr-1mid
T2M (type 2 myeloid cells) that contributes to the
cockroach-induced asthmatic exacerbation [49]. Fallon
et al. found that during Nippostrongylus brasiliensis
infection, IL-25-dependent Th2 cytokine-producing c-
kit+FceR1– NBNT cells played a key role at the initia-
tion of helminth expulsion [31]. Another IL-13-producing
myeloid cell is CD1d-dependent NK T cell-activated
macrophage which helped to translate SeV infection
into COPD independent of an adaptive immune
response [32]. In our study, the IL-10 OE-induced
CD11b+CD11c+CD49b+F4/80–Gr-1– cell appears to be a dif-
ferent cell type capable of producing robust IL-13 expres-
sion in the setting of IL-10 OE.
In our IL-10 OE mouse model, among all the genes that
are up-regulated by IL-10, IL-13 and MCP-1 are two most
highly induced genes. As IL-13 is a key player in regulating
mucus production during allergic airway inflammation
[50,51], IL-10 OE alone-induced immunopathological
changes in the lung might be due to this highly induced
IL-13 production. Furthermore, both IL-10 and IL-13 have
been reported to be able to drive MCP-1 expression
[52–54]. Besides MCP-1, other chemokines, such as CCL3
and RANTES were also up-regulated. For these chemok-
ines, whether IL-13 plays a direct regulatory role remains
to be determined by neutralization studies. Thus, IL-13, in
accordance with other chemokines, acts independently of
RSV-induced effector T cells and drives the recruitment of
pulmonary leucocytes, which can then lead to the immune
pathological changes in the lung. When wild-type mice
were infected with RSV, endogenous IL-10 expression
showed high expression at day 6 and then decreased by
day 8. This late phase IL-10 gene ‘shut down’ might have
beneficial effects to the host, i.e. preventing a further exac-
erbation of the immune pathological changes induced by
RSV. In our late IL-10 ‘turn on’ model, with the continued
presence of IL-10 an additive effect to the RSV-induced
immunopathological responses was observed, character-
ized by exacerbation of airway inflammation and goblet
cell hyperplasia. Therefore, investigating the gene regula-
tion of IL-10 during the course of RSV infection appears
to be important for understanding this common respira-
tory disease. It is also possible that the cellular sources of
IL-10 change during the course of RSV infection. It is
known that IL-10-producing cells include CD4+ and CD8+
T cells, dendritic cells, regulatory T cells (Treg), monocytes,
NK and NK T cells [12,44,45]. During both the innate
and adaptive immune responses against RSV infection,
antigen-specific CD4+ and CD8+ T cells play critical roles
in preventing excess inflammation by producing IL-10
[45]. Clinically, however, it has been reported that
monocyte-produced IL-10, especially under dysregulated
immune conditions, functions to enhance Th2 responses
[12]. Whether our late ‘turn on’ model explains such clini-
cal observations needs further investigation. With regard
to IL-13 production, it is possible that the source of IL-13
varies with the time post-infection. There might also be
transitions from the predominance of IL-13-producing
anti-viral effector T cells to the predominance of RSV-
independent myeloid cells, which is the target of ongoing
studies.
In summary, our study demonstrated a dual role for
IL-10 on the immune response to RSV. IL-10 inhibited RSV
induced inflammation, but conversely also induced strong
Th2-dominant immune responses, possibly via a different
mechanism and via a non-CD4+ T cell subset. Therefore,
when two opposite effects were occurring together, as seen
in the early IL-10 ‘turn on’ model, the anti-inflammatory
effects of IL-10 appear to be masked by the IL-10 ‘alone’
effects. These diverse responses could explain the conflict-
ing reports of IL-10 on the asthmatic phenotype as well
as other immune regulations. Although much remains
unknown, our study on the dual role of IL-10 provides
further mechanistic insight to explain some of the conflict-
ing reports on the role of IL-10 in regulating pathogen-
induced inflammation. Multiple factors, such as the timing
of IL-10 expression, the concentrations of IL-10 present in
the lung, the cellular target of IL-10 induced inflammation
and, furthermore, the genetic and epigenetic regulation on
IL-10 gene expression after infection need to be considered.
Besides, it also suggests that it is critical to determine the
appropriate time-frame and cell/molecular targets for con-
sidering neutralization of IL-10 in the setting of viral-
induced LRTI.
IL-10’s role in RSV-induced inflammation
277© 2012 British Society for Immunology, Clinical and Experimental Immunology, 172: 263–279
Acknowledgements
We thank Dr Keith Bishop at the University of Michigan for
providing the anti-CD4 depletion antibodies. We thank Dr
J. Erby Wilkinson at the University of Michigan for help
with the lung section immunohistology analysis. We also
thank Kelli McDonough at the Pediatrics Critical Care
Medicine Division for her careful reading and revision on
this manuscript. This work was supported by NIH Grants
RO1 GM66839-07 to T.P.S. and 5R01AI036302-12 to
N.W.L.
Disclosure
The authors declare that they have no conflicts of interest.
References
1 Corne JM, Holgate ST. Mechanisms of virus induced exacerba-
tions of asthma. Thorax 1997; 52:380–9.
2 Martinez FD. Definition of pediatric asthma and associated risk
factors. Pediatr Pulmonol Suppl 1997; 15:9–12.
3 Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW.
Respiratory syncytial virus infection results in airway hyperre-
sponsiveness and enhanced airway sensitization to allergen. J Clin
Invest 1997; 100:226–33.
4 Teichtahl H, Buckmaster N, Pertnikovs E. The incidence of respi-
ratory tract infection in adults requiring hospitalization for
asthma. Chest 1997; 112:591–6.
5 Hogg JC. Childhood viral infection and the pathogenesis of
asthma and chronic obstructive lung disease. Am J Respir Crit
Care Med 1999; 160:S26–8.
6 Holtzman MJ, Morton JD, Shornick LP et al. Immunity, inflam-
mation, and remodeling in the airway epithelial barrier:
epithelial–viral–allergic paradigm. Physiol Rev 2002; 82:19–46.
7 Prince GA, Capiau C, Deschamps M et al. Efficacy and safety
studies of a recombinant chimeric respiratory syncytial virus FG
glycoprotein vaccine in cotton rats. J Virol 2000; 74:10287–92.
8 Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC III,
Murphy BR. Enhanced pulmonary histopathology induced by res-
piratory syncytial virus (RSV) challenge of formalin-inactivated
RSV-immunized BALB/c mice is abrogated by depletion of
interleukin-4 (IL-4) and IL-10. J Virol 1994; 68:5321–5.
9 Hunter CA, Ellis-Neyes LA, Slifer T et al. IL-10 is required to
prevent immune hyperactivity during infection with Trypanosoma
cruzi. J Immunol 1997; 158:3311–6.
10 Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by
Lactococcus lactis secreting interleukin-10. Science 2000;
289:1352–5.
11 Murai H, Terada A, Mizuno M et al. IL-10 and RANTES are
elevated in nasopharyngeal secretions of children with respiratory
syncytial virus infection. Allergol Int 2007; 56:157–63.
12 Bont L, Heijnen CJ, Kavelaars A et al. Monocyte IL-10 production
during respiratory syncytial virus bronchiolitis is associated with
recurrent wheezing in a one-year follow-up study. Am J Respir
Crit Care Med 2000; 161:1518–23.
13 Schuurhof A, Janssen R, de Groot H et al. Local interleukin-10
production during respiratory syncytial virus bronchiolitis is asso-
ciated with post-bronchiolitis wheeze. Respir Res 2011; 12:121–7.
14 Chung HL, Kim WT, Kim JK et al. Relationship between atopic
status and nasal interleukin 10 and 11 levels in infants with respi-
ratory syncytial virus bronchiolitis. Ann Allergy Asthma Immunol
2005; 94:267–72.
15 Takanashi S, Hasegawa Y, Kanehira Y et al. Interleukin-10 level in
sputum is reduced in bronchial asthma, COPD and in smokers.
Eur Respir J 1999; 14:309–14.
16 Araujo MI, Hoppe B, Medeiros M, Jr et al. Impaired T helper 2
response to aeroallergen in helminth-infected patients with
asthma. J Infect Dis 2004; 190:1797–803.
17 Spight D, Zhao B, Haas M, Wert S, Denenberg A, Shanley TP.
Immunoregulatory effects of regulated, lung-targeted expression
of IL-10 in vivo. Am J Physiol Lung Cell Mol Physiol 2005;
288:L251–65.
18 Tekkanat KK, Maassab HF, Cho DS et al. IL-13-induced airway
hyperreactivity during respiratory syncytial virus infection is
STAT6 dependent. J Immunol 2001; 166:3542–8.
19 Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated
responses promote immunity to respiratory syncytial virus infec-
tion by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J
Immunol 2008; 38:2168–79.
20 Smit JJ, Lindell DM, Boon L, Kool M, Lambrecht BN, Lukacs NW.
The balance between plasmacytoid DC versus conventional DC
determines pulmonary immunity to virus infections. PLoS One
2008; 3:e1720.
21 Schaller MA, Neupane R, Rudd BD et al. Notch ligand Delta-like 4
regulates disease pathogenesis during respiratory viral infections
by modulating Th2 cytokines. J Exp Med 2007; 204:2925–34.
22 Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter
RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced
impairment in lung antibacterial host defense. J Immunol 1999;
162:392–9.
23 Mukherjee S, Lindell DM, Berlin AA et al. IL-17-induced pulmo-
nary pathogenesis during respiratory viral infection and exacerba-
tion of allergic disease. Am J Pathol 2011; 179:248–58.
24 Rudd BD, Smit JJ, Flavell RA et al. Deletion of TLR3 alters the pul-
monary immune environment and mucus production during res-
piratory syncytial virus infection. J Immunol 2006; 176:1937–42.
25 Tekkanat KK, Maassab H, Miller A, Berlin AA, Kunkel SL, Lukacs
NW. RANTES (CCL5) production during primary respiratory
syncytial virus infection exacerbates airway disease. Eur J
Immunol 2002; 32:3276–84.
26 Lukacs NW, Strieter RM, Warmington K, Lincoln P, Chensue SW,
Kunkel SL. Differential recruitment of leukocyte populations and
alteration of airway hyperreactivity by C-C family chemokines in
allergic airway inflammation. J Immunol 1997; 158:4398–404.
27 Schaller MA, Kallal LE, Lukacs NW. A key role for CC chemokine
receptor 1 in T-cell-mediated respiratory inflammation. Am J
Pathol 2008; 172:386–94.
28 Nakayama T, Yamashita M. Initiation and maintenance of Th2 cell
identity. Curr Opin Immunol 2008; 20:265–71.
29 Bishop DK, Chan Wood S, Eichwald EJ, Orosz CG. Immunobiol-
ogy of allograft rejection in the absence of IFN-gamma: CD8+
effector cells develop independently of CD4+ cells and CD40–
CD40 ligand interactions. J Immunol 2001; 166:3248–55.
30 Dolgachev V, Petersen BC, Budelsky AL, Berlin AA, Lukacs NW.
Pulmonary IL-17E (IL-25) production and IL-17RB+ myeloid
cell-derived Th2 cytokine production are dependent upon stem
cell factor-induced responses during chronic allergic pulmonary
disease. J Immunol 2009; 183:5705–15.
L. Sun et al.
278 © 2012 British Society for Immunology, Clinical and Experimental Immunology, 172: 263–279
31 Fallon PG, Ballantyne SJ, Mangan NE et al. Identification of an
interleukin (IL)-25-dependent cell population that provides IL-4,
IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med
2006; 203:1105–16.
32 Kim EY, Battaile JT, Patel AC et al. Persistent activation of an
innate immune response translates respiratory viral infection into
chronic lung disease. Nat Med 2008; 14:633–40.
33 Vermaelen K, Pauwels R. Accurate and simple discrimination of
mouse pulmonary dendritic cell and macrophage populations by
flow cytometry: methodology and new insights. Cytometry A
2004; 61:170–77.
34 Arase H, Saito T, Phillips JH, Lanier LL. Cutting edge: the mouse
NK cell-associated antigen recognized by DX5 monoclonal anti-
body is CD49b (alpha 2 integrin, very late antigen-2). J Immunol
2001; 167:1141–4.
35 Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G
on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to
granulocyte-differentiation antigen (Gr-1) detects members of the
Ly-6 family. J Immunol 1993; 151:2399–408.
36 Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial
virus-induced chemokine production: linking viral replication to
chemokine production in vitro and in vivo. J Infect Dis 2004;
189:1419–30.
37 Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Inter-
leukin 5 deficiency abolishes eosinophilia, airways hyperreactivity,
and lung damage in a mouse asthma model. J Exp Med 1996;
183:195–201.
38 Hogan SP, Foster PS. Cellular and molecular mechanisms involved
in the regulation of eosinophil trafficking in vivo. Med Res Rev
1996; 16:407–32.
39 John AE, Berlin AA, Lukacs NW. Respiratory syncytial virus-
induced CCL5/RANTES contributes to exacerbation of allergic
airway inflammation. Eur J Immunol 2003; 33:1677–85.
40 Lukacs NW. Role of chemokines in the pathogenesis of asthma.
Nat Rev Immunol 2001; 1:108–16.
41 Haeberle HA, Casola A, Gatalica Z et al. IkappaB kinase is a criti-
cal regulator of chemokine expression and lung inflammation in
respiratory syncytial virus infection. J Virol 2004; 78:2232–41.
42 Jiang XB, Wang ZD, Zhu Y et al. Inhibition of CD8+ T lym-
phocytes attenuates respiratory syncytial virus-enhanced allergic
inflammation. Respiration 2009; 77:76–84.
43 Smit JJ, Boon L, Lukacs NW. Respiratory virus-induced regulation
of asthma-like responses in mice depends upon CD8 T cells and
interferon-gamma production. Am J Pathol 2007; 171:1944–51.
44 Lloyd CM, Hawrylowicz CM. Regulatory T cells in asthma. Immu-
nity 2009; 31:438–49.
45 Sun J, Cardani A, Sharma AK et al. Autocrine regulation of pul-
monary inflammation by effector T-cell derived IL-10 during
infection with respiratory syncytial virus. PLoS Pathog 2011;
7:e1002173.
46 Zuany-Amorim C, Haile S, Leduc D et al. Interleukin-10 inhibits
antigen-induced cellular recruitment into the airways of sensitized
mice. J Clin Invest 1995; 95:2644–51.
47 Nakagome K, Dohi M, Okunishi K et al. In vivo IL-10 gene
delivery suppresses airway eosinophilia and hyperreactivity by
down-regulating APC functions and migration without impair-
ing the antigen-specific systemic immune response in a mouse
model of allergic airway inflammation. J Immunol 2005;
174:6955–66.
48 Richardson JY, Ottolini MG, Pletneva L et al. Respiratory syncytial
virus (RSV) infection induces cyclooxygenase 2: a potential target
for RSV therapy. J Immunol 2005; 174:4356–64.
49 Petersen BC, Budelsky AL, Baptist AP, Schaller MA, Lukacs NW.
Interleukin-25 induces type 2 cytokine production in a steroid-
resistant interleukin-17RB+ myeloid population that exacerbates
asthmatic pathology. Nat Med 2012; 18:751–8.
50 Lukacs NW, Tekkanat KK, Berlin A et al. Respiratory syncytial
virus predisposes mice to augmented allergic airway responses
via IL-13-mediated mechanisms. J Immunol 2001; 167:1060–
5.
51 Park JW, Taube C, Yang ES et al. Respiratory syncytial virus-
induced airway hyperresponsiveness is independent of IL-13 com-
pared with that induced by allergen. J Allergy Clin Immunol 2003;
112:1078–87.
52 Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW,
Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human
lung fibroblasts. Implication in asthma. J Clin Invest 1998;
101:2129–39.
53 Ikeda T, Sato K, Kuwada N et al. Interleukin-10 differently regu-
lates monocyte chemoattractant protein-1 gene expression
depending on the environment in a human monoblastic cell line,
UG3. J Leukoc Biol 2002; 72:1198–205.
54 Ip WK, Wong CK, Lam CW. Interleukin (IL)-4 and IL-13
up-regulate monocyte chemoattractant protein-1 expression in
human bronchial epithelial cells: involvement of p38 mitogen-
activated protein kinase, extracellular signal-regulated kinase 1/2
and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signal-
ling pathways. Clin Exp Immunol 2006; 145:162–72.
IL-10’s role in RSV-induced inflammation
279© 2012 British Society for Immunology, Clinical and Experimental Immunology, 172: 263–279
